Latest Insider Transactions at Catalent, Inc. (CTLT)
This section provides a real-time view of insider transactions for Catalent, Inc. (CTLT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Catalent, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Catalent, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 01
2023
|
Patricia Hunt Pres. Consumer Health Div |
BUY
Grant, award, or other acquisition
|
Direct |
1,952
+14.95%
|
-
|
|
Aug 01
2023
|
Patricia Hunt Pres. Consumer Health Div |
SELL
Open market or private sale
|
Direct |
161
-1.73%
|
$7,567
$47.95 P/Share
|
|
Aug 01
2023
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
BUY
Grant, award, or other acquisition
|
Direct |
4,790
+18.54%
|
-
|
|
Aug 01
2023
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
SELL
Open market or private sale
|
Direct |
195
-1.19%
|
$9,165
$47.86 P/Share
|
|
Aug 01
2023
|
Thomas W Hawkeswood Pres. Pharma Prod Delivery Div |
BUY
Grant, award, or other acquisition
|
Direct |
2,306
+23.73%
|
-
|
|
Aug 01
2023
|
Thomas W Hawkeswood Pres. Pharma Prod Delivery Div |
SELL
Open market or private sale
|
Direct |
258
-4.81%
|
$12,126
$47.97 P/Share
|
|
Aug 01
2023
|
Scott Gunther SVP, Quality & Reg. Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
5,322
+15.45%
|
-
|
|
Aug 01
2023
|
Scott Gunther SVP, Quality & Reg. Affairs |
SELL
Open market or private sale
|
Direct |
190
-0.79%
|
$8,930
$47.9 P/Share
|
|
Aug 01
2023
|
Michael J Grippo SVP, Strategy & Corp. Dev. |
BUY
Grant, award, or other acquisition
|
Direct |
6,209
+20.74%
|
-
|
|
Aug 01
2023
|
Michael J Grippo SVP, Strategy & Corp. Dev. |
SELL
Open market or private sale
|
Direct |
276
-0.78%
|
$12,972
$47.26 P/Share
|
|
Aug 01
2023
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
BUY
Grant, award, or other acquisition
|
Direct |
8,870
+8.51%
|
-
|
|
Aug 01
2023
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
SELL
Open market or private sale
|
Direct |
281
-0.16%
|
$13,207
$47.23 P/Share
|
|
Aug 01
2023
|
Lorenzo Carletti SVP Global Ops Ph & Cons Hlth |
BUY
Grant, award, or other acquisition
|
Direct |
3,903
+31.46%
|
-
|
|
Aug 01
2023
|
Lorenzo Carletti SVP Global Ops Ph & Cons Hlth |
SELL
Open market or private sale
|
Direct |
383
-7.68%
|
$18,001
$47.77 P/Share
|
|
Aug 01
2023
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
SELL
Open market or private sale
|
Direct |
62
-0.11%
|
$2,914
$47.8 P/Share
|
|
Aug 01
2023
|
Steven L Fasman EVP & Chief Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,885
+14.15%
|
-
|
|
Aug 01
2023
|
Steven L Fasman EVP & Chief Admin Officer |
SELL
Open market or private sale
|
Direct |
1,637
-1.33%
|
$76,939
$47.24 P/Share
|
|
Jul 26
2023
|
Alessandro Maselli President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
46,396
+34.63%
|
-
|
|
Jul 05
2023
|
Matti Masanovich SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,864
+50.0%
|
-
|
|
Jul 01
2023
|
J Martin Carroll Director |
BUY
Grant, award, or other acquisition
|
Direct |
555
+2.57%
|
-
|
|
May 01
2023
|
Manja Boerman Pres. BioModalities Division |
SELL
Open market or private sale
|
Direct |
1,446
-9.12%
|
$70,854
$49.86 P/Share
|
|
May 01
2023
|
Mario Gargiulo SVP, Ops, Biologics Europe |
SELL
Open market or private sale
|
Direct |
678
-10.67%
|
$33,222
$49.86 P/Share
|
|
Jan 23
2023
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
SELL
Open market or private sale
|
Direct |
643
-3.76%
|
$31,507
$49.36 P/Share
|
|
Dec 05
2022
|
Manja Boerman Pres. BioModalities Division |
SELL
Open market or private sale
|
Direct |
780
-4.69%
|
$39,780
$51.7 P/Share
|
|
Oct 31
2022
|
Michael J Grippo SVP, Strategy & Corp. Dev. |
SELL
Open market or private sale
|
Direct |
2,451
-12.11%
|
$159,315
$65.83 P/Share
|
|
Oct 27
2022
|
Peter Zippelius Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,149
+25.73%
|
-
|
|
Oct 27
2022
|
Christa Kreuzburg Director |
SELL
Payment of exercise price or tax liability
|
Direct |
421
-3.12%
|
$27,786
$66.27 P/Share
|
|
Oct 27
2022
|
Christa Kreuzburg Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,149
+23.54%
|
-
|
|
Oct 27
2022
|
Gregory T Lucier Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,149
+14.11%
|
-
|
|
Oct 27
2022
|
Donald E Morel Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,149
+6.63%
|
-
|
|
Oct 27
2022
|
Jack L Stahl Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,149
+10.25%
|
-
|
|
Oct 27
2022
|
Madhavan Balachandran Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,149
+16.87%
|
-
|
|
Oct 27
2022
|
Michael J Barber Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,149
+39.35%
|
-
|
|
Oct 27
2022
|
J Martin Carroll Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,149
+16.82%
|
-
|
|
Oct 27
2022
|
Rolf A Classon Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,149
+10.25%
|
-
|
|
Oct 27
2022
|
Rosemary A Crane Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,149
+19.73%
|
-
|
|
Oct 27
2022
|
Karen Flynn Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,149
+19.3%
|
-
|
|
Oct 27
2022
|
John J Greisch Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
4,149
+19.73%
|
-
|
|
Oct 10
2022
|
Thomas W Hawkeswood Pres. Pharma Prod Delivery Div |
SELL
Open market or private sale
|
Direct |
930
-14.78%
|
$71,610
$77.46 P/Share
|
|
Sep 19
2022
|
Karen Murphy Santiago VP & Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,421
+45.49%
|
-
|
|
Sep 15
2022
|
Karen Flynn Director |
BUY
Grant, award, or other acquisition
|
Direct |
245
+1.82%
|
-
|
|
Aug 31
2022
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
SELL
Open market or private sale
|
Direct |
2,216
-11.48%
|
$197,224
$89.59 P/Share
|
|
Aug 26
2022
|
Michael A. Riley Pres. Bio Product Delivery Div |
SELL
Open market or private sale
|
Direct |
2,491
-27.42%
|
$259,064
$104.07 P/Share
|
|
Aug 26
2022
|
Scott Gunther SVP, Quality & Reg. Affairs |
SELL
Open market or private sale
|
Direct |
1,639
-6.4%
|
$170,456
$104.07 P/Share
|
|
Aug 25
2022
|
Kay A Schmidt SVP, Enterprise Functions |
SELL
Open market or private sale
|
Direct |
1,321
-7.06%
|
$136,063
$103.04 P/Share
|
|
Aug 25
2022
|
Michael A. Riley Pres. Bio Product Delivery Div |
SELL
Open market or private sale
|
Direct |
1,482
-14.03%
|
$152,646
$103.04 P/Share
|
|
Aug 25
2022
|
Ricardo Pravda Chief Transformation Officer |
SELL
Open market or private sale
|
Direct |
1,747
-8.03%
|
$179,941
$103.04 P/Share
|
|
Aug 25
2022
|
Alessandro Maselli President & CEO |
SELL
Open market or private sale
|
Direct |
4,646
-10.14%
|
$478,538
$103.04 P/Share
|
|
Aug 25
2022
|
Patricia Hunt Pres. Consumer Health Div |
SELL
Open market or private sale
|
Direct |
339
-3.51%
|
$34,917
$103.04 P/Share
|
|
Aug 25
2022
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
SELL
Open market or private sale
|
Direct |
1,517
-7.28%
|
$156,251
$103.04 P/Share
|